Analysts expect ProMIS Neurosciences to report a Q3 2026 loss of $1.28 per share on zero revenue, with the stock currently trading at $4.16 compared to an average analyst price target of $42.75. The primary focus for investors remains the clinical progress of PMN310, the company’s lead antibody candidate for Alzheimer’s disease, which is currently in Phase 1b development.
Management recently confirmed the PRECISE-AD trial is fully enrolled, with topline data expected in Q1 2027. Investors are also closely monitoring management's guidance on the company’s $53 million cash position, which is intended to fund operations through major clinical milestones and beyond the upcoming data readouts.